|1.||Pastan, Ira: 54 articles (12/2015 - 06/2002)|
|2.||Hassan, Raffit: 45 articles (12/2015 - 11/2002)|
|3.||Hino, Okio: 26 articles (10/2014 - 09/2006)|
|4.||Creaney, Jenette: 23 articles (07/2015 - 11/2003)|
|5.||Ho, Mitchell: 23 articles (01/2015 - 05/2005)|
|6.||Robinson, Bruce W S: 17 articles (10/2014 - 11/2003)|
|7.||Maeda, Masahiro: 16 articles (10/2014 - 09/2006)|
|8.||Hagiwara, Yoshiaki: 15 articles (01/2014 - 09/2006)|
|9.||Zhang, Jingli: 13 articles (12/2015 - 05/2005)|
|10.||Scholler, Nathalie: 12 articles (07/2015 - 03/2007)|
06/01/2014 - "Antitumor efficacy of BAY 94-9343 correlated with the amount of mesothelin expressed and was generally superior to that of standard-of-care regimen resulting in complete tumor eradication in most of the models. "
12/08/2015 - "We therefore developed a zirconium-89 (89Zr) labeled anti-mesothelin antibody (89Zr-AMA) to study its biodistribution in human pancreatic tumor bearing mice. "
11/01/2015 - "The BD studies also demonstrated a positive correlation between tumor size (or the level of shed mesothelin in blood) and liver uptake. "
04/01/2015 - "Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors."
03/01/2015 - "Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-κB/PI3K/Akt signaling pathways. "
01/01/2013 - "The new molecule, SS1-LR/GGS/8M, has cytotoxic activity comparable with SS1P on several mesothelin-expressing cell lines and remarkably improved activity on primary cells from patients with mesothelioma. "
07/01/2015 - "The majority of recent studies have evaluated soluble mesothelin in effusions in a diagnostic setting for mesothelioma. "
01/01/2014 - "The results of this study show that the combination of mesothelin and miR-103a-3p improves the diagnostic performance of individual blood-based biomarker to detect malignant mesothelioma. "
01/01/2014 - "The aim of this study was to assess the performance of the combination of mesothelin and miR-103a-3p as blood-based biomarker for mesothelioma. "
11/01/2008 - "The aim of this study was to investigate whether serum N-ERC/mesothelin, an NH3-terminal fragment of mesothelin, and plasma OPN reflect chemotherapeutic effect in patients with mesothelioma. "
|3.||Ovarian Neoplasms (Ovarian Cancer)
04/01/2012 - "Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125."
01/01/2015 - "The biodistribution studies further confirmed the targeting efficiency and higher biodistribution of immunodendrimers into the mesothelin protein expressing ovarian cancer cells. "
09/01/2013 - "Recent studies show that mesothelin gene is up-regulated in patients with serous ovarian cancer. "
06/01/2008 - "The purpose of this study was to explore the therapeutic utility of a mesothelin promoter-based CRAd in a murine model of ovarian cancer, using noninvasive in vivo imaging. "
01/01/2008 - "The normal biologic function of mesothelin is unknown but recent studies have shown that it binds to CA-125 and may play a role in the peritoneal spread of ovarian cancer. "
|4.||Pancreatic Neoplasms (Pancreatic Cancer)
01/01/2014 - "An increasing number of studies have examined the ability of mesothelin to be a marker for the diagnosis of pancreatic cancer (PCa). "
01/01/2013 - "Our previous study has shown that mesothelin (MSLN) is a potential immunotherapeutic target for pancreatic cancer. "
01/01/2012 - "The aim of the present study was to evaluate the effects of mesothelin on proliferation and apoptosis in pancreatic cancer cells with different p53 status and to explore its signal pathway. "
09/15/2011 - "The goal of this study is to treat pancreatic cancer with RIT by targeting mesothelin. "
02/01/2008 - "This study revealed novel functions of mesothelin and suggested a new therapeutic vaccine strategy whereby mesothelin is targeted to control pancreatic cancer progression."
03/01/2007 - "Immunocytochemical study of the expression of mesothelin in fine-needle aspiration biopsy specimens of pancreatic adenocarcinoma."
09/01/2003 - "In this study, immunohistochemical labeling for 2 of these markers, PSCA and mesothelin, appears highly specific for pancreatic adenocarcinoma in FNA specimens and useful in categorizing cytologically suspicious lesions."
05/10/2015 - "53% of advanced lung adenocarcinomas expressed mesothelin to some degree; high mesothelin expression, defined as mesothelin positivity in more than 25% of cells, was found in 24% of patients. "
05/10/2015 - "We immunohistochemically evaluated the intensity, and the percentage of cells expressing mesothelin in 93 advanced lung adenocarcinomas. "
04/01/2014 - "Loss of immunohistochemical staining for the protein product of the SMAD4 gene and positive staining for mesothelin support a diagnosis of ductal adenocarcinoma. "
|3.||Biological Markers (Surrogate Marker)
|4.||Small Interfering RNA (siRNA)
|7.||Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
|9.||megakaryocyte potentiating factor
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)
|4.||Quantum Dots (Quantum Dot)